LGR5 and hepatoblastoma: In hepatoblastoma, the Wnt and Akt signaling pathways are important targets of aprepitant, as this NK-1R antagonist blocks the canonical Wnt pathway (a downregulation of the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) and axis inhibition protein 2 (AXIN2) Wnt target genes occurs along with a decrease in β-catenin) and reduces the phosphorylation of p70S6K/4E-BP1/2 (Table 2) [89].